Method acute edema paranoid schizophrenia

 

(57) Abstract:

The invention relates to medicine, namely to psychiatry. The method allows to reduce terms of acute edema paranoid schizophrenia and to reduce the frequency and severity of side effects. To do this, intramuscularly antipsychotic long-acting drugs. In this weekly dose of haloperidol decanoate and piportila L4 is 200-300 mg, Klopicksola depot 600-800 mg treatment 3-6 injections.

The invention relates to medicine, namely to psychiatry, and can be used for the treatment of patients with acute bouts of paranoid schizophrenia.

There is a method of acute edema paranoid schizophrenia through the use of psychotropic drugs. (In Russian). G. J. Ph.D, A. A. Neduva "Treatment of the mentally ill". M. Medicine, 1988, S. 224-244).

The disadvantage of this method is the severity of side effects and complications (30-100%), insufficient level of efficiency (40-60%), the long duration of the relief of acute conditions (up to 2-3 months), the complexity of the control patients receiving medication, the difficulties of caring for this population of patients, high consumption of medicinal drugs close to the proposed method is acute edema paranoid schizophrenia using intramuscular antipsychotic drugs extended 4-week action in particular, haloperidol decanoate dose of 400-600 mg 1 every 4 weeks (In the materials of the Soviet-Hungarian Symposium on the haloperidol decanoate. M. 1988, S. 5-20).

The disadvantage of this method is the lack of therapeutic effect in 55% and the presence of side effects in 60-100% of cases, as well as difficulties in their elimination.

The aim of the present invention is the reduction of terms acute edema paranoid schizophrenia, a reduction in the frequency and severity of side effects, increasing the number of patients with cropped acute attacks.

This goal is achieved by the fact that neuroleptic drugs extended 4-week steps to enter 1 time per week, with a weekly dose of haloperidol decanoate and spoiled L4 is 200-300 mg, Klopicksola depot 600-800 mg treatment 3-6 injections.

Not derived from a well-known patterns of pharmacotherapy is the fact to reduce the side effects with increasing doses of antipsychotic drugs extended 4-week steps up to a certain level, which improves the efficiency of acute edema paranoid, sisir is at an acute attack of paranoid schizophrenia after clinical and laboratory examination administered 1 time per week intramuscular haloperidol decanoate or piportil L4 in the weekly dose of 200-300 mg or Klopicksola depot 600-800 mg and the dose required to offset trihexyphenidyl 3-18 mg daily, depending on individual tolerability of psychotropic drugs. Weekly monitor and record how the dynamics of mental States (formalized scales), and the severity of various side effects. The course of treatment 3-6 injections. After cupping psychosis dose of neuroleptic prolonged action gradually reduced to the level of support.

Example: the Patient K., 1968 R. and/b N 6245.

Received: 05.07.90.

Diagnosis: schizophrenia paroxysmal paranoid, hallucinatory-paranoid syndrome. Mentally ill since 1983, when suddenly decreased mood, began to feel that others badly they treat it, condemn it, want to harm her. Was hospitalized in a psychiatric hospital where they were treated with psychotropic drugs - neuroleptics and andidepressants. In the follow-up was twice hospitalized in connection with various delusions, auditory hallucinations, inappropriate behaviour. The duration of the last two

attacks was 90 and 120 days. Before this hospitalization, the patient's condition deteriorated again appeared auditory hallucinations, delusional ideas, relationships, harassment, expressed fear and anxiety, tension, insomnia, decreased significantly nastroenie the dose of 30 mg for 20 days proved to be ineffective due to the severity of side effects in the form of tremor, akathisia, scologin crises.

After the clinical and laboratory examination the patient was assigned to haloperidol decanoate 200 mg intramuscularly 1 time per week and concealer trihexyphenidyl 18 mg per day. A week after the first injection in the patient's condition was marked by a clear positive trend: slightly decreased the relevance of delusional experiences, less and less long steel auditory hallucinations was significantly reduced anxiety and fear, tension, stabilized sleep. Within a week the side effects were insignificant. By the end of the second week after the second intramuscular injection of haloperidol decanoate dose of 200 mg completely disappeared fear and anxiety was moderate improvement in mood, the patient stopped counting around his enemies, even more rare are the hallucinatory phenomena. The patient willingly talked about their experiences, it became less of a closed, fenced off, a rare electoral communication with patients.

After the third injection of haloperidol decanoate dose of 200 mg intramuscularly patient became much calmer and more appropriately, significantly decreased rezonansa colouring thinking, began the battle of ideas, others are much less relevant, has elements of critical attitude to the previous attacks.

By the end of the fourth week almost all psychopathological

symptoms, which constitutes the basis of this psychotic attack, underwent a considerable reduction. Disappeared depression, fear, anxiety, tension leveled mood, much less actual steel remaining separate delusional ideas, rarely and for a short period of time there were auditory hallucinations, thought and behavior have become more adequate. Have a desire to read books and magazines, watch TV, communicate with a wider range of patients and members of the medical staff.

In a subsequent dose of haloperidol decanoate was reduced to 50 mg intramuscularly 1 time per week, then 1 every 2-3 weeks. In connection with distinct stabilization of the patient was discharged under the supervision of the district psychiatrist, continued outpatient receiving maintenance doses of psychotropic drugs, and within months her condition was satisfactory.

Thus, treatment with haloperidol-decanoate 1 time per week 200 mg intramuscularly the periods 90 and 120 days, side effects were not observed, unlike the previous attacks, kurirovavshih traditional methods pharmacotherapy.

In this way the treatment of 35 patients with acute bouts of paranoid schizophrenia with acute side effects of ongoing traditional pharmacotherapy and lack of therapeutic effect within 2-6 months. As a result of applying our proposed method, the positive effect of treatment was observed in 27 patients (75%). Terms of edema was significantly reduced to 4-6 weeks.

Method 1 acute edema paranoid schizophrenia by intramuscular antipsychotic long-acting drugs, including haloperidol decanoate, characterized in that the drugs are injected once a week, with the dose of haloperidol decanoate and piportila L4is 200 to 300 mg, Klopicksola depot 600 to 800 mg, the course of treatment is 3 to 6 injections.

 

Same patents:
The invention relates to medicine, namely to the pathology and can be used for the treatment of patients with vibration disease (WB)
The invention relates to medicine, namely to psychiatry

The invention relates to medicine, namely to the production of medicines on the basis of [N-methyl-N-(D-glyukopiranozil)ammonium-2(acridin-9-one-10-yl)acetate]cycloferon, and can be used for the treatment of atherosclerosis and its complications

The invention relates to new heterocycles compounds, more particularly to a new heterocycles compounds which are inhibitors of the enzyme 5-lipoxygenase (5-LO)

The invention relates to medicine, namely to anesthesiology, and can be used in anesthetic ensuring operations on the brain
The invention relates to medicine, namely to psychiatry and can be used in the treatment of alcoholism

The invention relates to veterinary medicine, namely the production of medicines on the basis of N-methyl-N-D-glyukopiranozil/ammonium-2-/acridin-9-one-10-Il/ acetate - cycloferon and can be used for the treatment of viral diseases in animals

FIELD: organic chemistry, natural compounds, medicine, oncology.

SUBSTANCE: invention represents new saponin mixtures used for inhibition of initiation and activation of mammalian epithelial cell in pre-malignant or malignant state, for stimulation of apoptosis of mammalian malignant cell, prophylaxis of anomalous proliferation of mammalian epithelial cell, for treatment of inflammatory and regulation of angiogenesis in mammal. These mixtures are isolated form plants of species Acacia victoriae. Also, invention relates to methods for their applying. These compounds can comprise triterpene component, such as acacic or oleanolic acid to which oligosaccharides and monoterpenoid components are joined. Mixtures and compounds elicit properties associated with regulation of apoptosis and cytotoxicity of cells and strong anti-tumor effect with respect to different tumor cells.

EFFECT: valuable medicinal properties of compositions.

43 cl, 53 tbl, 50 dwg, 44 ex

FIELD: organic chemistry, chemical technology, medicine, oncology, pharmacy.

SUBSTANCE: invention relates to new derivative of taxane of the formula (I):

that elicits strong antitumor effect. Also, invention relates to intermediates substances, a method for preparing compound of the formula (I), a method for preparing 1,14-β-hydroxy-1,14-carbonate-baccatin III-derivatives substituted with isoserine residue at position 3 and to pharmaceutical composition based on compounds of the formula (I). Invention provides preparing new derivative of taxane that elicits higher activity and reduced toxicity as compared with paclitaxel.

EFFECT: improved preparing method, enhanced and valuable medicinal properties of compound.

10 cl, 7 tbl, 6 ex

FIELD: organic chemistry, medicine, pharmacy.

SUBSTANCE: invention relates to new derivatives of borrelidin of the general formula (I)

wherein R represents the group of the general formulae -COOR1, -CONR2R3, -CONR4CONR2R5 or -CH2OR6 wherein R1 represents (C2-C6)-alkyl group, (C1-C6)-alkyl group substituted with hydroxyl group or 5-8-membered saturated nitrogen-containing heterocyclic group (it can comprise oxygen atom in addition to nitrogen atom) or 5-6-membered nitrogen-containing aromatic heterocyclic group or (C3-C6)-cycloalkyl group; R2 and R3 are similar or different and represent independently hydrogen atom or (C1-C6)-alkyl group that can be substituted optionally with hydroxyl, (C2-C5)-alkoxycarbonyl or 5-8-membered saturated nitrogen-containing heterocyclic group (it can comprises oxygen atom in addition to nitrogen atom) or 5-6-membered aromatic homocyclic group or aromatic heterocyclic group comprising oxygen and/or nitrogen atom, 5-6-membered cycloalkyl or heteroaryl group; R4 and R5 are similar or different and represent independently hydrogen atom or (C3-C6)-cycloalkyl group; R6 represents hydrogen atom; also, invention relates to tautomers, solvates of these compounds, their mixtures and acid-additive salts. Also, invention relates to pharmaceutical compositions comprising compounds of the general formula (I) as an active component. Angiogenesis inhibitors of the present invention inhibit formation of new vessels in tissues of live organisms and can be used for prophylaxis and inhibition of the angiogenesis process arising in the tumor proliferation, and for prophylaxis of formation of tumor metastasis. Invention provides preparing new derivatives of borrelidin eliciting the value physiological effect.

EFFECT: valuable medicinal properties of compounds.

8 cl, 15 ex

FIELD: medicine, hepatology.

SUBSTANCE: at achieving alkaline phosphatase of 580 U and more one should introduce ursodesoxycholic acid at the dosage of 15-20 mg/kg and orlistate at the dosage of 90-100 mg twice or thrice daily for patients with steatohepatitis. According to normalization of clinical and biochemical values of blood analyses it is possible to conclude upon successfulness of therapy performed. The method provides clinic-laboratory remission of the disease.

EFFECT: higher efficiency of therapy.

3 ex

FIELD: medicine, pharmacy.

SUBSTANCE: invention relates to new acid-additive nitrate salts of compounds taken among salbutamol, cetirizine, loratidine, terfenadine, emedastine, ketotifen, nedocromil, ambroxol, dextrometorphan, dextrorphan, isoniazide, erythromycin and pyrazinamide. Indicated salts can be used for treatment of pathology of respiratory system and elicit an anti-allergic, anti-asthmatic effect and can be used in ophthalmology also. Indicated salts have less adverse effect on cardiovascular and/or gastroenteric systems as compared with their non-salt analogues. Also, invention proposes pharmaceutical compositions for preparing medicinal agents for treatment of pathology of respiratory system and comprising above indicated salts or nitrate salts of metronidazol or aciclovir.

EFFECT: improved and valuable properties of compounds.

6 cl, 5 tbl, 19 ex

FIELD: organic chemistry, medicine, oncology, pharmacy.

SUBSTANCE: invention relates to a new pentacyclic compound derivative of taxane represented by the formula:

wherein R1 represents dimethylaminomethyl group or morpholinomethyl group; R2 represents halogen atom or alkoxy-group comprising from 1 to 6 carbon atoms, or its salt eliciting an antitumor effect, and to a medicine agent based on its. Invention provides preparing new derivatives of taxane eliciting the valuable biological effect.

EFFECT: valuable medicinal properties of compound.

13 cl, 1 dwg, 4 tbl, 16 ex

FIELD: woodworking industry.

SUBSTANCE: invention relates to methods for recovering and purifying native bioflavonoids: dihydroquercitine and dihydrokaempferol from larch wood extracts. Method of recovering bioflavonoids from larch wood extracts is characterized by that freeze-dried extract is dissolved in ethylacetone/water mixture composed in specified proportion, specified amount of resulting solution is introduced into column filled with urea (sorbent) preliminarily equilibrated with ethylacetate, and column is then eluted with an ester and/or ketone having boiling point below 120°C, or with ethylacetate/acetone mixture at specified ratio. Eluate is collected and evaporated until crystallization is observed and then cooled. Separated crystals are rinsed and dried.

EFFECT: enabled single-step process for separating dihydroquercitine and dihydrokaempferol from resinous impurities and other polymeric compounds, reduced process expenses, and reduced environmental impact.

4 cl, 1 dwg

FIELD: organic chemistry, medicine, pharmacy.

SUBSTANCE: invention relates to new semi-synthetic taxanes of the formula (1):

wherein R and R1 can be similar or different and represent hydrogen atom (H), (C1-C18)-acyl group, benzoyl group; R2 and R3 represent hydrogen atom (H) or R2 and R3 in common form carbonate or thiocarbonate residue; R4 represents benzoyl group optionally substituted at meta-position; R' represents hydrogen atom (H) or (C1-C4)-alkyl; R'' represents (C1-C4)-alkyl or phenyl; R''' represents tert.-butoxy-group under condition that R and R1 both can't represent hydrogen atom (H). Also, invention relates to a pharmaceutical composition based on compounds of the formula (1) eliciting an anti-tumor, anti-angiogenic and anti-arthrosis effect. Invention provides preparing new compounds eliciting cytotoxicity comparable with cytotoxicity of other taxanes but showing reduced systemic toxicity that can be administrated by intravenous and oral routes.

EFFECT: valuable medicinal properties of compounds and pharmaceutical compositions.

6 cl, 1 tbl, 7 ex

FIELD: medicine, therapy, gastroenterology.

SUBSTANCE: method involves preliminary assay of the disorder type in gallbladder motor contraction and bile-excretion ways followed by prescribing thermal low-mineralized hydrocarbonate-sodium-sulfate-calcium-magnesium mineral water in the dose by 200-300 ml, 3 times per a day, 1 h before eating, tubages № 3 with mineral water, bathes and shower with mineral water every day for 10-14 days. In the hypotonic type of motor activity method involves mineral water at temperature 25-30°C, and in the hypertonic type - at temperature 38-40°C. Method provides accelerating in scars formation of ulcers and epithelization of erosions in gastroduodenal system, to prevent frequent exacerbations and to reduce activity of Chelicobacter-induced inflammation.

EFFECT: improved therapy method.

4 tbl, 2 ex

FIELD: organic chemistry, medicine, oncology, pharmacy.

SUBSTANCE: invention relates to new taxanes of the general formula (I)

wherein R2 means benzoyloxy-group; R7 means hydroxyl (OH); R9 means keto-group; R10 means R10aCOO-; R10 means (C2-C6)-alkyl, (C2-C6)-alkenyl, (C3-C6)-cycloalkyl or 5-6-membered heteroaromatic group wherein heteroatom represents oxygen atom (O), sulfur atom (S) or nitrogen atom (N); R14 means hydrogen atom (H); X3 means (C2-C6)-alkyl, (C2-C6)-alkenyl, (C3-C6)-cycloalkyl, phenyl substituted possibly with nitro-group (-NO2), 5-6-membered heteroaromatic group wherein heteroatom represents O, S or N; X5 means -COX10, -COOX10; X10 means (C2-C6)-alkyl, (C2-C6)-alkenyl, (C3-C6)-cycloalkyl, phenyl or 5-6-membered heteroaromatic group wherein heteroatom represents O, S, N; Ac means acetyl. Compounds of the formula (I) elicit antitumor activity.

EFFECT: valuable medicinal properties of compounds.

68 cl, 1 tbl, 6 ex

Up!